1
|
Rangaswamy S, Sreenivasulu R, Babu VR, Syed T, Kapavarapu RK, Jayaprakash HV, Abbaraju VDNK. Design, Synthesis, Anticancer Evaluation, and Molecular Docking Studies of Oxazole-Incorporated Naphthyridine Derivatives. Chem Biodivers 2023; 20:e202300466. [PMID: 37864549 DOI: 10.1002/cbdv.202300466] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2023] [Revised: 10/19/2023] [Accepted: 10/20/2023] [Indexed: 10/23/2023]
Abstract
A novel series of oxazole incorporated naphthyridine (21 a-j) derivatives were designed and, synthesized followed by screening of their anticancer activity profiles against human breast cancer (MCF-7), human lung cancer (A549) and human prostate (PC3 & DU-145) cancer cell lines by employing MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide] assay using etoposide as the positive control. Of these compounds, N-(6-chloro-3-(4-(3,4,5-trimethoxyphenyl)oxazol-2-yl)-1,5-naphthyridin-4-yl)oxazol-2-amine with 3,4,5-trimethoxy substituent on the aryl moiety attached to oxazole ring showed potent anticancer activity against PC3, A549, MCF-7, and DU-145 cell lines with IC50 values of 0.13±0.095 μM; 0.10±0.084 μM; 0.18±0.087 μM and 0.15±0.076 μM respectively. Apart from this, compounds N-(6-chloro-3-(4-(3,5-dimethoxyphenyl)oxazol-2-yl)-1,5-naphthyridin-4-yl)oxazol-2-amine, N-(6-chloro-3-(4-(4-methoxyphenyl)oxazol-2-yl)-1,5-naphthyridin-4-yl)oxazol-2-amine, and N-(6-chloro-3-(4-(3,5-dimethylphenyl)oxazol-2-yl)-1,5-naphthyridin-4-yl)oxazol-2-amine also showed better anticancer activities against four cancer cell lines screened for. These activities were also validated through the molecular docking simulations, which further indicated demonstration of better interaction energy and profile by these compounds.
Collapse
Affiliation(s)
- Singamsetty Rangaswamy
- Department of Chemistry, GITAM School of Science, Gandhi Institute of Technology and Management (Deemed to be University), Visakhapatnam, Andhra Pradesh, 530045, India
| | - Reddymasu Sreenivasulu
- Department of Chemistry, University College of Engineering (Autonomous), Jawaharlal Nehru Technological University, Kakinada, Andhra Pradesh, 533003, India
| | - Vankayala Ramesh Babu
- Department of Chemistry, GITAM School of Science, Gandhi Institute of Technology and Management (Deemed to be University), Visakhapatnam, Andhra Pradesh, 530045, India
| | - Tasqeeruddin Syed
- Department of Pharmaceutical Chemistry, College of Pharmacy, King Khalid University, Abha, Saudi Arabia
| | - Ravi Kumar Kapavarapu
- Department of Pharmaceutical Chemistry and Phytochemistry, Nirmala College of Pharmacy, Atmakur, Mangalagiri, Andhra Pradesh, 522503, India
| | - Hulikunte Veeranna Jayaprakash
- Department of Chemistry, Sri Siddartha Institute of Technology, Sri Siddartha Academy of Higher Education (Deemed to be University) Tumkur, Karnataka, 572107, India
| | - Venkata Durga Nagendra Kumar Abbaraju
- Department of Chemistry, GITAM School of Science, Gandhi Institute of Technology and Management (Deemed to be University), Visakhapatnam, Andhra Pradesh, 530045, India
| |
Collapse
|
2
|
Mohiuddin M, Kasahara K. Cisplatin Activates the Growth Inhibitory Signaling Pathways by Enhancing the Production of Reactive Oxygen Species in Non-small Cell Lung Cancer Carrying an EGFR Exon 19 Deletion. Cancer Genomics Proteomics 2021; 18:471-486. [PMID: 33994369 DOI: 10.21873/cgp.20273] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2021] [Revised: 04/01/2021] [Accepted: 04/06/2021] [Indexed: 12/29/2022] Open
Abstract
BACKGROUND/AIM Cisplatin is a potent anticancer drug for treating several types of cancer, including non-small-cell lung cancer (NSCLC). In this study, we investigated the cytotoxicity and mechanism of action of cisplatin in the human NSCLC cell line PC9. MATERIALS AND METHODS PC9 cells were treated with cisplatin for 72 h and then evaluated by a cell viability assay, DAPI staining, Giemsa staining, apoptosis assay, membrane permeability assay, cell cycle assay, ROS assay, SA-β-gal staining, TUNEL assay and Western blotting. RESULTS Our findings revealed that the cytotoxic activity was associated with an apoptotic signaling pathway in response to DNA damage. Cisplatin exerted a significant concentration-dependent antiproliferative effect on PC9 cells. Cells subjected to cisplatin treatment showed morphological indications of apoptosis. Cell cycle arrest was related to the restriction of E2F-1 action by the cyclin-dependent protein kinase inhibitor p21WAF1/CIP1 Cisplatin induced apoptosis of PC9 cells by upregulating Fas, FasL, Bak, and tBID expression and PARP proteolytic cleavage. Cisplatin also reduced the mitochondrial membrane potential (MMP) and initiated a caspase cascade. Furthermore, the apoptotic impact of cisplatin depended on reactive oxygen species (ROS), as confirmed by ROS generation. CONCLUSION Cisplatin induced anticancer effects through cell cycle arrest, ROS generation and caspase activation, resulting in cell apoptosis. Overall, the results show the mechanism by which cisplatin works as an anticancer drug in the treatment of NSCLC.
Collapse
Affiliation(s)
- Md Mohiuddin
- Department of Respiratory Medicine, Kanazawa University, Ishikawa, Japan
| | - Kazuo Kasahara
- Department of Respiratory Medicine, Kanazawa University, Ishikawa, Japan
| |
Collapse
|
3
|
Al-romaizan AN, Jaber TS, Ahmed NS. Novel 1,8-Naphthyridine Derivatives: Design, Synthesis and in vitro screening of their cytotoxic activity against MCF7 cell line. OPEN CHEM 2019. [DOI: 10.1515/chem-2019-0097] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
AbstractA series of new 2-phenyl-7-methyl-1,8-naphthyridine derivatives with variable substituents at C3 were synthesized for an in vitro evaluation of their anticancer activity against human breast cancer cell line (MCF7). On one hand, compounds 3f, 6f, 8c, and 10b showed IC50 values (6.53, 7.88, 7.89, 7.79 μM, respectively) compared to that of the mentioned drug staurosparine (IC50 = 4.51 μM). On the other hand, derivatives 10c, 8d, 4d, 10f and 8b displayed better activity than staurosporin with IC50 values (1.47, 1.62, 1.68, 2.30, 3.19 μM, respectively).
Collapse
Affiliation(s)
- Abeer N. Al-romaizan
- Chemistry Dept., Faculty of Science, King Abdulaziz Universty, Jeddah, Saudi Arabia
| | - Thoraya S. Jaber
- Chemistry Dept., Faculty of Science, King Abdulaziz Universty, Jeddah, Saudi Arabia
| | - Nesreen S. Ahmed
- Chemistry Dept., Faculty of Science, King Abdulaziz Universty, Jeddah, Saudi Arabia
- Department of Therapeutic Chemistry, Pharmaceutical and Drug Industries Division, National Research Center, El Buhouth Street, Dokki, Cairo12622, Egypt
| |
Collapse
|
4
|
Heo G, Kang D, Park C, Kim SJ, Choo J, Lee Y, Yoo JW, Jung Y, Lee J, Kim ND, Chung HY, Moon HR, Im E. Pro-apoptotic effect of the novel benzylidene derivative MHY695 in human colon cancer cells. Oncol Lett 2019; 18:3256-3264. [PMID: 31452803 PMCID: PMC6704326 DOI: 10.3892/ol.2019.10664] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2018] [Accepted: 06/20/2019] [Indexed: 12/29/2022] Open
Abstract
The induction of apoptosis is a useful strategy in anti-cancer research. Various Moon Hyung Yang (MHY) compounds have been developed as novel anti-cancer drug candidates; in the present study, the pro-apoptotic effects of (Z)-5-(3-ethoxy-4- hydroxybenzylidene)-2-thioxothiazolidin-4-one (MHY695) on HCT116 human colon cancer cells were assessed. MTT assays were performed to investigate the dose-dependent cytotoxic effects of MHY695 on HCT116 cells. Immunofluorescence staining and flow cytometry analyses were performed to identify apoptotic cell death, and western blot analysis was used to investigate the apoptotic-signaling pathways. A mouse xenograft model was also used to determine the effects of MHY695 in vivo. MHY695 decreased the viability of HCT116 cells and induced apoptotic cytotoxicity. The apoptotic mechanisms induced by MHY695 involved the dephosphorylation of Bcl-2-associated agonist of cell death protein following protein kinase B inactivation, induced myeloid leukaemia cell differentiation protein and BH3-interacting domain death agonist truncation, caspase-3 and -9 activation and poly (ADP-ribose) polymerase cleavage. In addition, MHY695 significantly suppressed tumor growth in the mouse xenograft model, compared with the vehicle control. Notably, MHY695 exhibited potent anti-cancer effects in four different types of human colon cancer cell line, including Caco-2, DLD-1, HT-29 and HCT116. Additionally, MHY695 showed reduced cytotoxicity in NCM460, normal colonic epithelial cells. Furthermore, MHY-induced cytotoxicity in colon cancer cells was independent of the tumor suppressor protein p53. Collectively, these observations suggested that MHY695 may be a novel drug for the treatment of colon cancer.
Collapse
Affiliation(s)
- Gwangbeom Heo
- College of Pharmacy, Pusan National University, Geumjeong-gu, Busan 46241, Republic of Korea
| | - Dongwan Kang
- College of Pharmacy, Pusan National University, Geumjeong-gu, Busan 46241, Republic of Korea
| | - Chaeun Park
- College of Pharmacy, Pusan National University, Geumjeong-gu, Busan 46241, Republic of Korea
| | - Su Jin Kim
- College of Pharmacy, Pusan National University, Geumjeong-gu, Busan 46241, Republic of Korea
| | - Jieun Choo
- College of Pharmacy, Pusan National University, Geumjeong-gu, Busan 46241, Republic of Korea
| | - Yunna Lee
- College of Pharmacy, Pusan National University, Geumjeong-gu, Busan 46241, Republic of Korea
| | - Jin-Wook Yoo
- College of Pharmacy, Pusan National University, Geumjeong-gu, Busan 46241, Republic of Korea
| | - Yunjin Jung
- College of Pharmacy, Pusan National University, Geumjeong-gu, Busan 46241, Republic of Korea
| | - Jaewon Lee
- College of Pharmacy, Pusan National University, Geumjeong-gu, Busan 46241, Republic of Korea
| | - Nam Deuk Kim
- College of Pharmacy, Pusan National University, Geumjeong-gu, Busan 46241, Republic of Korea
| | - Hae Young Chung
- College of Pharmacy, Pusan National University, Geumjeong-gu, Busan 46241, Republic of Korea
| | - Hyung Ryong Moon
- College of Pharmacy, Pusan National University, Geumjeong-gu, Busan 46241, Republic of Korea
| | - Eunok Im
- College of Pharmacy, Pusan National University, Geumjeong-gu, Busan 46241, Republic of Korea
| |
Collapse
|
5
|
Flader A, Parpart S, Ehlers P, Langer P. Synthesis of pyrrolo[1,2-a]naphthyridines by Lewis acid mediated cycloisomerization. Org Biomol Chem 2017; 15:3216-3231. [DOI: 10.1039/c7ob00343a] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Functionalized pyrrolo[1,2-a]naphthyridines were synthesized by application of PtCl2 and Bi(OTf)3 as simple Lewis acids in a cycloisomerization reaction.
Collapse
Affiliation(s)
- Anika Flader
- Universität Rostock
- Institut für Chemie
- 18059 Rostock
- Germany
- Leibniz-Institut für Katalyse e.V. an der Universität Rostock
| | - Silvio Parpart
- Universität Rostock
- Institut für Chemie
- 18059 Rostock
- Germany
| | - Peter Ehlers
- Universität Rostock
- Institut für Chemie
- 18059 Rostock
- Germany
- Leibniz-Institut für Katalyse e.V. an der Universität Rostock
| | - Peter Langer
- Universität Rostock
- Institut für Chemie
- 18059 Rostock
- Germany
- Leibniz-Institut für Katalyse e.V. an der Universität Rostock
| |
Collapse
|
6
|
Fan K, Li X, Cao Y, Qi H, Li L, Zhang Q, Sun H. Carvacrol inhibits proliferation and induces apoptosis in human colon cancer cells. Anticancer Drugs 2015. [PMID: 26214321 DOI: 10.1097/cad.0000000000000263] [Citation(s) in RCA: 68] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
Colon cancer is one of the most common malignancies worldwide and has a high mortality rate. Carvacrol is a major component of oregano and thyme essential oils and shows antitumor properties. Here, we investigated the effects of carvacrol on the proliferation and apoptosis of two human colon cancer cell lines, HCT116 and LoVo, and studied the molecular mechanisms of its antitumor properties. We found that carvacrol inhibited the proliferation and migration of the two colon cancer cell lines in a concentration-dependent manner. Cell invasion was suppressed after carvacrol treatment by decreasing the expression of matrix metalloprotease-2 (MMP-2) and MMP-9. Carvacrol treatment also caused cell cycle arrest in the G2/M phase and decreased cyclin B1 expression. Finally, carvacrol induced cell apoptosis in a dose-dependent manner. At the molecular level, carvacrol downregulated the expression of Bcl-2 and induced the phosphorylation of the extracellular-regulated protein kinase and protein kinase B (p-Akt). In parallel, carvacrol upregulated the expression of Bax and c-Jun N-terminal kinase. These results indicate that carvacrol might induce apoptosis in colon cancer cells through the mitochondrial apoptotic pathway and the MAPK and PI3K/Akt signaling pathways. Together, our results suggest that carvacrol may have therapeutic potential for the prevention and treatment of colon cancer.
Collapse
Affiliation(s)
- Kai Fan
- Departments of aPathophysiology bPathology and cPharmacology, Harbin Medical University-Daqing dDepartment of Surgery, Fifth Clinical College of Harbin Medical University, Daqing, Heilongjiang, China
| | | | | | | | | | | | | |
Collapse
|
7
|
Madaan A, Verma R, Kumar V, Singh AT, Jain SK, Jaggi M. 1,8-Naphthyridine Derivatives: A Review of Multiple Biological Activities. Arch Pharm (Weinheim) 2015; 348:837-60. [DOI: 10.1002/ardp.201500237] [Citation(s) in RCA: 55] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2015] [Revised: 10/10/2015] [Accepted: 10/14/2015] [Indexed: 12/16/2022]
Affiliation(s)
- Alka Madaan
- Cell Biology Lab; Dabur Research Foundation; Sahibabad, Ghaziabad Uttar Pradesh India
| | - Ritu Verma
- Cell Biology Lab; Dabur Research Foundation; Sahibabad, Ghaziabad Uttar Pradesh India
| | - Vivek Kumar
- Chemical Research Lab; Dabur Research Foundation; Sahibabad, Ghaziabad Uttar Pradesh India
| | - Anu T. Singh
- Cell Biology Lab; Dabur Research Foundation; Sahibabad, Ghaziabad Uttar Pradesh India
| | - Swatantra K. Jain
- Department of Medical Biochemistry, HIMSR and Department of Biotechnology; Jamia Hamdard; New Delhi India
| | - Manu Jaggi
- Cell Biology Lab; Dabur Research Foundation; Sahibabad, Ghaziabad Uttar Pradesh India
| |
Collapse
|
8
|
LIM HYUNSOOK, KANG YONGJUNG, SUNG BOKYUNG, KIM SEONHEE, KIM MINJEONG, KIM HYERIM, KIM SEONGJIN, CHOI YUNGHYUN, MOON HYUNGRYONG, CHUNG HAEYOUNG, KIM NAMDEUK. Novel dihydrobenzofuro[4,5-b][1,8]naphthyridin-6-one derivative, MHY-449, induces cell cycle arrest and apoptosis via the downregulation of Akt in human lung cancer cells. Oncol Rep 2015; 34:2431-8. [DOI: 10.3892/or.2015.4208] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2015] [Accepted: 07/16/2015] [Indexed: 11/06/2022] Open
|
9
|
Kim SH, Kang YJ, Sung B, Kim DH, Lim HS, Kim HR, Kim SJ, Yoon JH, Moon HR, Chung HY, Kim ND. MHY-449, a novel dihydrobenzofuro[4,5-b][1,8]naphthyridin-6-one derivative, mediates oxidative stress-induced apoptosis in AGS human gastric cancer cells. Oncol Rep 2015; 34:288-94. [PMID: 25998412 DOI: 10.3892/or.2015.3984] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2015] [Accepted: 04/02/2015] [Indexed: 11/06/2022] Open
Abstract
MHY-449 is a novel dihydrobenzofuro[4,5-b][1,8]naphthyridin-6-one derivative designed and synthesized as a potential anticancer agent. The present study aimed to examine the anticancer activity and underlying mechanism of MHY-449. The cell viability assay performed in AGS human gastric carcinoma cells demonstrated that MHY-449 inhibited cell proliferation in a concentration-dependent manner. MHY-449 induced AGS cell death via apoptosis. The underlying molecular mechanism of MHY-449-mediated apoptosis was also investigated. MHY-449 promoted the upregulation of Fas and Fas-ligand, and activation of caspase-8, suggesting the involvement of a Fas-mediated extrinsic pathway in MHY-449-induced apoptosis. In addition, it was found that MHY-449-induced apoptosis was accompanied by the upregulation of Bax, p21(WAF1/CIP1), p27(KIP1), and p53 and suppression of Bcl-2. MHY-449 exposure activated the caspase cascade and subsequent poly(ADP-ribose) polymerase (PARP) cleavage. Furthermore, the pan-caspase inhibitor, Z-VAD-FMK, significantly attenuated MHY-449-induced apoptosis, indicating that the apoptosis was caspase-dependent. Moreover, the apoptogenic effect of MHY-449 was reactive oxygen species (ROS)-dependent. This result was confirmed by the induction of ROS by MHY-449 and by evidence that the scavenging of ROS by N-acetyl-L-cysteine inhibited MHY-449-induced cell death. Taken together, these results demonstrated that MHY-449 triggers apoptosis via caspase activation and ROS production. This result provides a novel mechanistic explanation and a basis for developing this compound as a novel candidate for human cancer therapy.
Collapse
Affiliation(s)
- Seon Hee Kim
- College of Pharmacy, Molecular Inflammation Research Center for Aging Intervention (MRCA), Pusan National University, Busan 609-735, Republic of Korea
| | - Yong Jung Kang
- College of Pharmacy, Molecular Inflammation Research Center for Aging Intervention (MRCA), Pusan National University, Busan 609-735, Republic of Korea
| | - Bokyung Sung
- College of Pharmacy, Molecular Inflammation Research Center for Aging Intervention (MRCA), Pusan National University, Busan 609-735, Republic of Korea
| | - Dong Hwan Kim
- College of Pharmacy, Molecular Inflammation Research Center for Aging Intervention (MRCA), Pusan National University, Busan 609-735, Republic of Korea
| | - Hyun Sook Lim
- College of Pharmacy, Molecular Inflammation Research Center for Aging Intervention (MRCA), Pusan National University, Busan 609-735, Republic of Korea
| | - Hye Rim Kim
- College of Pharmacy, Molecular Inflammation Research Center for Aging Intervention (MRCA), Pusan National University, Busan 609-735, Republic of Korea
| | - Seong Jin Kim
- College of Pharmacy, Molecular Inflammation Research Center for Aging Intervention (MRCA), Pusan National University, Busan 609-735, Republic of Korea
| | - Jeong-Hyun Yoon
- College of Pharmacy, Molecular Inflammation Research Center for Aging Intervention (MRCA), Pusan National University, Busan 609-735, Republic of Korea
| | - Hyung Ryong Moon
- College of Pharmacy, Molecular Inflammation Research Center for Aging Intervention (MRCA), Pusan National University, Busan 609-735, Republic of Korea
| | - Hae Young Chung
- College of Pharmacy, Molecular Inflammation Research Center for Aging Intervention (MRCA), Pusan National University, Busan 609-735, Republic of Korea
| | - Nam Deuk Kim
- College of Pharmacy, Molecular Inflammation Research Center for Aging Intervention (MRCA), Pusan National University, Busan 609-735, Republic of Korea
| |
Collapse
|
10
|
Yuan L, Zhang Y, Xia J, Liu B, Zhang Q, Liu J, Luo L, Peng Z, Song Z, Zhu R. Resveratrol induces cell cycle arrest via a p53-independent pathway in A549 cells. Mol Med Rep 2014; 11:2459-64. [PMID: 25515619 PMCID: PMC4337473 DOI: 10.3892/mmr.2014.3100] [Citation(s) in RCA: 52] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2014] [Accepted: 11/12/2014] [Indexed: 01/28/2023] Open
Abstract
Resveratrol, a non-flavone polyphenol compound, has a chemopreventive and chemotherapeutic effect against the progression of multiple types of cancer, including lung cancer. However, the molecular mechanism underlying the effects of resveratrol on cancer remain to be elucidated. In the present study, using an MTT assay, it was demonstrated that resveratrol inhibited cell proliferation in a concentration- and time-dependent manner. In addition, morphological features were observed in the A549, human lung cancer cell line, which included cell shrinkage, cells became distorted, certain cells became rounded and there was a concentration-dependent increase in the number of sloughed cells. Cell cycle analysis revealed that resveratrol may induce cell cycle arrest in the G0/G1 phase by downregulating the expression levels of cyclin D1, cyclin-dependent kinase (CDK)4 and CDK6, and upregulating the expression levels of the CDK inhibitors, p21 and p27. The immunofluorescence and western blot analysis results revealed that resveratrol upregulated the nuclear expression of p53 in A549 cells. Further studies have demonstrated that p53 downregulation did not contribute to the G0/G1 cell cycle arrest induced by resveratrol. In addition, resveratrol had no effect on the expression of p21, through use of the p53 inhibitor, pifithrin-α. The present study may offer a scientific basis for the further in-depth evaluation of resveratrol in the association of p53 and cell cycle arrest.
Collapse
Affiliation(s)
- Long Yuan
- Department of Respiratory Medicine, Affiliated Hospital of Guangdong Medical College, Zhanjiang, Guangdong 524001, P.R. China
| | - Yongrong Zhang
- Department of Respiratory Medicine, Affiliated Hospital of Guangdong Medical College, Zhanjiang, Guangdong 524001, P.R. China
| | - Juan Xia
- Laboratory of Hepatobiliary Surgery, Zhanjiang Key Laboratory of Hepatobiliary Diseases, Affiliated Hospital of Guangdong Medical College, Zhanjiang, Guangdong 524001, P.R. China
| | - Bin Liu
- Laboratory of Hepatobiliary Surgery, Zhanjiang Key Laboratory of Hepatobiliary Diseases, Affiliated Hospital of Guangdong Medical College, Zhanjiang, Guangdong 524001, P.R. China
| | - Qingyu Zhang
- Laboratory of Hepatobiliary Surgery, Zhanjiang Key Laboratory of Hepatobiliary Diseases, Affiliated Hospital of Guangdong Medical College, Zhanjiang, Guangdong 524001, P.R. China
| | - Jie Liu
- Laboratory of Hepatobiliary Surgery, Zhanjiang Key Laboratory of Hepatobiliary Diseases, Affiliated Hospital of Guangdong Medical College, Zhanjiang, Guangdong 524001, P.R. China
| | - Liming Luo
- Department of Respiratory Medicine, The Fourth Hospital of Zhanjiang, Zhanjiang, Guangdong 524001, P.R. China
| | - Zhou Peng
- Department of Respiratory Medicine, The Fourth Hospital of Zhanjiang, Zhanjiang, Guangdong 524001, P.R. China
| | - Zeqing Song
- Department of Respiratory Medicine, Affiliated Hospital of Guangdong Medical College, Zhanjiang, Guangdong 524001, P.R. China
| | - Runzhi Zhu
- Laboratory of Hepatobiliary Surgery, Zhanjiang Key Laboratory of Hepatobiliary Diseases, Affiliated Hospital of Guangdong Medical College, Zhanjiang, Guangdong 524001, P.R. China
| |
Collapse
|
11
|
LEE SUNHWA, KANG YONGJUNG, SUNG BOKYUNG, KIM DONGHWAN, LIM HYUNSOOK, KIM HYERIM, KIM SEONGJIN, YOON JEONGHYUN, MOON HYUNGRYONG, CHUNG HAEYOUNG, KIM NAMDEUK. MHY-449, a novel dihydrobenzofuro[4,5-b][1,8] naphthyridin-6-one derivative, induces apoptotic cell death through modulation of Akt/FoxO1 and ERK signaling in PC3 human prostate cancer cells. Int J Oncol 2014; 44:905-11. [DOI: 10.3892/ijo.2014.2257] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2013] [Accepted: 12/23/2013] [Indexed: 11/05/2022] Open
|
12
|
Kim MK, Kang YJ, Kim DH, Hossain MA, Jang JY, Lee SH, Yoon JH, Chun P, Moon HR, Kim HS, Chung HY, Kim ND. A novel hydroxamic acid derivative, MHY218, induces apoptosis and cell cycle arrest through downregulation of NF-κB in HCT116 human colon cancer cells. Int J Oncol 2013; 44:256-64. [PMID: 24190633 DOI: 10.3892/ijo.2013.2163] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2013] [Accepted: 10/14/2013] [Indexed: 11/06/2022] Open
Abstract
Colorectal cancer (CRC) is one of the most common malignant diseases and frequent cause of cancer deaths in the world. In spite of the significant advances in conventional therapeutic approaches to CRC, most patients ultimately die of their disease. There is a need to develop novel preventive approaches for this malignancy. This study was carried out to investigate the anticancer effect of MHY218, a hydroxamic acid derivative, in HCT116 human colon cancer cells. Treatment of cells with MHY218 resulted in growth inhibition and induction of apoptosis in a concentration-dependent manner. MHY218 induced G2/M phase arrest in the cell cycle progression which was observed by flow cytometry analysis, and a decrease in the protein expression of cyclin B1 and its activating partners Cdc25C and Cdc2. MHY218 also caused an increase in the expression levels of p21(WAF1/CIP1), a G2/M phase inhibitor, in a p53-independent pathway. The induction of apoptosis was observed by decreased viability, DNA fragmentation, cleavage of poly(ADP-ribose) polymerase, alteration in the ratio of Bax/Bcl-2 protein expression, and activation of caspase-3, -8 and -9. In addition, MHY218 treatment showed downregulation of the expression levels of the transcription factor nuclear factor-kappa B (NF-κB) in the nucleus, which has been reported to be implicated in the apoptotic cell death of several types of cancer cells, suppression of TNF-α-induced NF-κB activation, inhibition of cyclooxygenase-2 expression, repression of matrix metalloproteinase-9 activation and decrease of 5-lipoxygenase in a concentration-dependent manner. These results suggest that MHY218 may be a useful candidate to be used in the chemoprevention and/or treatment of colon cancer.
Collapse
Affiliation(s)
- Mi Kyeong Kim
- Division of Pharmacy, College of Pharmacy, Molecular Inflammation Research Center for Aging Intervention (MRCA), Pusan National University, Busan 609-735, Republic of Korea
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|